Featured Jobs
|
Senior ERISA Compliance Analyst Employee Fiduciary, LLC
|
|
MAP Retirement
|
|
Heller Pension Associates, Inc.
|
|
Daybright Financial
|
|
Relationship Manager for Defined Contributions Daybright Financial
|
|
Retirement Plan Installation & Document Manager Fringe Benefit Group
|
|
Defined Contribution Account Manager Nova 401(k) Associates
|
|
July Business Services
|
|
Executive Assistant / Sales Support M2B Retirement Consulting LLC
|
|
EPIC RPS
|
|
Relationship Manager for Defined Benefits Daybright Financial
|
|
Senior Counsel - Benefits and Total Rewards Tyson Foods
|
|
Independent Retirement
|
|
Retirement Compliance Consultant Navia Benefit Solutions
|
Free Publications
|
|
The Future of Metabolic Health and Weight Loss Drugs: Projecting Mortality Reductions
Swiss Re Group 
Sept. 22, 2025 "Widespread use of GLP-1 weight loss drugs to treat obesity could reduce cumulative all-cause mortality by up to 6.4% in the US and 5.1% in the UK general populations by 2045 ... GLP-1 drugs may reshape claims experience across mortality, longevity and medical insurance products.... In the US and UK general populations, [the] modelled baseline scenario projects 4% and 3.2% reductions in cumulative all-cause mortality respectively by 2045, based on GLP-1 drug use." MORE >> |
| Please click here to report this link if it is broken (for example, if you see a "404 File Not Found" error message after you click on the linked news item's title). |
| An important word about authorship: BenefitsLink® created this link to the news item, but we are not the news item's author (unless expressly shown above). |